PPT-Discovery of novel cardiovascular drug targets

CarTarDis Car diovascular Tar get Dis covery Publicprivate partnership 13 partners 8 countries project budget 80M Eur Start 1 Oct 2013 for 4 years Coordinator CarTarDis. By Andreas Dr Lorenz M.Mayr Drug Discovery World Summer 2006 Miniaturisation ofassay developmentand screening In recent years we have seen a strong increase in the number of chemicalcompounds and mole an Industrial Process. How are drugs . discovered and developed?. Dr Steve Carney, s.carney@elsevier.com. Managing Editor, . Drug Discovery Today. What’s my background?. First degree in Biochemistry. – . get ready for the show. Weidong Zhang. Pfizer. 1. Outline. Overview of omics technology. Application of omics in drug discovery. Case studies from pre-clinical to phase II/III. 2. 3. Omics provide paramount view of biological cascade. Properties: . Optimizing Pharmacokinetics and Safety During Drug . Discovery. ACS Short Course. Li Di and Edward H. Kerns. Introduction to Drug-Like Properties. Few research compounds will become drugs because they lack sufficient pharmacokinetics (PK) and safety. Distinguished University Professor Lecture. Presented on January 29, 2015 by Paul Erhardt, PhD. UT DUP and Director of the Center for Drug Design and Development (CD3). paul.erhardt@utoledo.edu. 1. Outline. Please Sign Up:. . Name. . Email (. Onyen. is fine, or …). . Are You . ENRolled. ?. Dept. & Advisor (Lab?). . Tentative Title (“????” Is OK). . When:. Next Week, Early, Oct., Nov., Late. the future is now. Robert Plenge, MD, PhD. Broad Institute. Medical and Population Genetics (MPG). October 1, 2015. The Problem. http://. csdd.tufts.edu. /. Phase II/III failures drive high cost of drug development. Gerald J. Wyckoff. Training modes. Are we training . genomicists. to deal with the right problems?. Are the training modalities we’re using proper?. What questions should we be looking at?. Problems in Drug Discovery. linking diseases, drivers, targets and drugs. via multi-omics, clinical, imaging and perturbation data fusion. Nathalie Pochet, Ph.D.. Assistant Professor, Harvard Medical School. Associate Scientist, Brigham and Women’s Hospital. Robert Plenge, MD, PhD. ASBMR. September 15, 2016. Our two fundamental challenges. Cost. to develop an asset has increased by . 1/3. rd. since 2010. Average peak . sales. per asset has . halved since 2010. Shari L. Targum, MD, MPH, FACC. Medical Officer. U.S. Food and Drug Administration. Detecting cardiac safety signals. Common, drug-related. : can detect in placebo-controlled, clinical trials, compare to background rate. 1. Dr. Abd El Raheim Donia. Generally,. . a drug . can be . defined . as a . substance that . induces . a response . within the human . body.. Dr. Abd El Raheim Donia. 2. FDA Definition . of a . Drug. Research Professor. Center for Neurodegenerative Disease Research. University of Pennsylvania. CNDR AD Drug Discovery-. From Plaques to Tangles. Amyloid. Plaques. Extracellular. Compact and diffuse. at . BCCC. YOU BELONG HERE. What is a Cardiovascular Monitor Technician?. A valued member of the health care team responsible for surveillance of patient cardiac monitors. Technician will perform EKG test to monitor and record cardiac activity. The technician is able to read and measure the patient’s rhythm strips and notify changes to healthcare providers. .